2012News & Press Release

  • Press Release
    NHI price listing for NPC-08 (Antineoplastic Agent Gliadel 7.7mg for Implant)
  • Press Release
    Apply for marketing approval of NPC-05 (Talc)
  • Press Release
    Shiomura, CEO gave a lecture at National Institute of Biomedical Innovation
  • Press Release
    Approval received for Manufacturing and Marketing of NPC-08 (Antineoplastic Agent Gliadel 7.7mg for Implant)
  • Press Release
    NPC-12 (Sirolimus) has been specified for orphan drug
  • Press Release
    Shiomura, CEO gave a lecture at Parent Association of Alternating hemiplegia of childhood
  • Press Release
    Plenary meeting of Sales & Marketing held for two days
  • Press Release
  • Press Release
    Completion of clinical experience investigation for neonatal seizure for Nobelbar 250mg for Injection
  • Press Release
    Submitted application for approval of Manufacturing and Marketing Authorization of NPC-01 (Ultra low dose hormones preparation)
  • Press Release
    Licensing Agreement on Sirolimus for Japan was concluded with Pfizer
  • Press Release
    Medical Information eXpress, interview with Shiomura, CEO on PRESIDENT column, May 2012
  • Press Release
    Shiomura, CEO gave a lecture at Patients Association for Distal Myopathies Symposium
  • Press Release
    The 9th Ordinary General Meeting of Shareholders
  • Press Release
  • Press Release
    Sales start for Foscavir® by own sales force
  • Press Release
    Training session for all employees held in Atami, two days, one night
  • Press Release
    Establishment of Tokyo Distribution Center in Saitama City
  • Press Release
  • Press Release
    MA transfer of Foscavir® from AstraZeneca Japan under license agreement with Clinigen
  • Press Release
Page top